Physician Information2023-12-01T20:21:12-05:00

WM Information for Physicians

Our goal is to make the selection of information here useful to the medical community at large.  Thus the information here may not necessarily be easily consumed by the public.  But all are welcome to this collection of WM-related information.

Essential Information: A Physician’s Guide

November 17th, 2023|

This booklet provides a compilation of current knowledge on the diagnosis, treatment, and established protocols for WM.  Complete with references to published papers, throughout, it has been modified with a small number of Canadian-specific footnotes.  Authored by two WM specialist MDs from the Bing Center for WM at the Dana-Farber Cancer Institute, it is presented in partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF).

Management of WM-Related Amyloidosis: IWWM-11 Consensus Panel 6

April 18th, 2023|

Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenström macroglobulinemia (WM).  Their report is available here.

Clinical Trial Priorities for WM: IWWM-11 Consensus Panel 7

April 15th, 2023|

Consensus Panel 7 (CP7) of the 11th International Workshop on WM was convened to examine the current generation of completed and ongoing clinical trials involving novel agents, consider updated data on WM genomics, and make recommendations on the design and prioritization of future clinical trials.  Their report is available here.

COVID-19 Prophylaxis and Management: IWWM-11 Consensus Panel 5

April 15th, 2023|

Consensus Panel 5 (CP5) of the 11th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-11; held in October 2022) was tasked with reviewing the current data on the coronavirus disease-2019 (COVID-19) prophylaxis and management in patients with Waldenstrom’s Macroglobulinemia (WM).  Their report is available here.

Multi-omic Analysis Yields Significant WM Insights

March 3rd, 2023|

Partially funded by the WMFC and presented at ASH in December, 2022, this research identified three subtypes of WM.

The full abstract that Dr. Hunter presented at ASH is available here.

Two other WM-related abstracts using the multiomic analysis from Dr. Hunter’s research were also presented at ASH:

  • An in-depth investigation into why epigenomic regulation is so important to MYD88 mutations is available here
  • The data also has been applied to investigating why ibrutinib (and by extension other BTK inhibitors) may result in long Progression-Free Survival (PFS); that abstract is available here


Donate today:

Join the WMFC and stay in the loop!

Get the latest news, events and membership information via email.

Go to Top